Loading stock data…
IMDX
$5.85+0.13 (+2.27%)
Market ClosedLast close Jun 9
Insight Molecular Diagnostics Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insight Molecular Diagnostics Inc. in the Healthcare sector is trading at $5.85. Wall Street consensus targets $8.33 (3 analysts), implying a +42.5% move over the next 12 months. The stock is currently 31% below its 52-week high of $8.51, remaining 14.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +42.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.85
Potential Downside
0%
Whystock Fair Value$5.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
447.49%
Volume
Today's trading volume
137,561
Recent News
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission
Insight Molecular Diagnostics now sits under a refreshed analyst narrative, with a price target that has moved to US$12 per share alongside an updated fair value estimate of US$10.50. Analysts linking this change to the recent US$26m offering and the pending GraftAssureDx FDA submission frame the new target as closely tied to funding progress and upcoming regulatory milestones. As you read on, you will see how these shifting assumptions and catalysts are shaping the story and how you can keep...
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ...
Insight Molecular Diagnostics Inc (IMDX) showcases international expansion and regulatory progress, while navigating financial hurdles and market uncertainties.
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones
Insight Molecular Diagnostics is back in focus as analysts update their narrative around a new $12 price target while the fair value estimate holds at $8.33. That shift in target is being linked to views on funding visibility after the recent $26m offering and expectations around an upcoming FDA submission for GraftAssureDx, as well as differing opinions on execution and financing risk. Read on to see how these moving pieces shape the evolving story and what to watch as new information...
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst
The latest update to Insight Molecular Diagnostics has seen the analyst price target move to US$12, while the fair value estimate remains at US$8.33 per share. Analysts linking this shift to the recent US$26M capital raise and the upcoming GraftAssureDx FDA submission see both reduced near term financing risk and a potential regulatory catalyst as key drivers. Read on to see how these moving parts shape the evolving story and what to watch as the narrative develops. Stay updated as the Fair...
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst
The raised price target from $8 to $12 puts Insight Molecular Diagnostics more firmly on the radar for investors tracking valuation shifts. Analysts are linking this higher price target to the recent $26,000,000 capital raise and the upcoming FDA submission for GraftAssureDx, which they identify as key factors behind the updated outlook. The following sections explain how this evolving analyst narrative could influence how you follow the story from here. Stay updated as the Fair Value for...